Claims for Patent: 9,249,172

Summary for Patent: 9,249,172

Title:	Pyrazole derivatives
Abstract:	Disclosed are pyrazole compounds of general formula (I), wherein R, R.sub.1, R.sub.c, R.sub.d, R.sub.e, R.sub.f, X, Y, Z, A and B are as defined in the application. These compounds are active as inhibitors of poly(ADP-ribose)polymerase (PARP) and are useful in methods for treating diseases or conditions mediated by PARP, including breast cancer and malignant melanoma. ##STR00001##
Inventor(s):	Li; Chenxi (Suzhou, CN), Shen; Weisheng (Suzhou, CN), Fang; Yang (Suzhou, CN), Le; Xiaoyong (Suzhou, CN)
Assignee:	HANDE PHARMA LIMITED (Suzhou, Jiangsu Province, CN) HANDE STARLAKE BIOSCIENXE CO., LTD. (Suzou, Jiangsu Province, CN)
Application Number:	13/698,548
Patent Claims:	1. A compound of general formula (I) or a pharmaceutically acceptable salt thereof: ##STR00014## wherein: A and B together with carbons to which A and B attach represent optionally substituted C.sub.6-10 aryl, or optionally substituted C.sub.3-10 cyclohydrocarbyl; R.sub.c,R.sub.d, R.sub.e and R.sub.f are independently selected from hydrogen, optionally substituted C.sub.1-6 alkyl and optionally substituted C.sub.1-6 acyl; R.sub.1 is independently selected from the group consisting of hydrogen, optionally substituted C.sub.1-6 alkyl and optionally substituted C.sub.1-6 haloalkyl; R is independently selected from the group consisting of hydrogen, optionally substituted C.sub.1-6 alkyl, optionally substituted C.sub.1-6 haloalkyl, C.sub.3-18 heterocyclyl optionally substituted with C.sub.1-6 alkyl or C.sub.1-6 haloalkyl or C.sub.3-12 cycloalkyl, optionally substituted C.sub.6-10 aryl, and optionally substituted C.sub.7-16 arylalkyl, wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulphur; and X represents oxygen or sulphur; Y and Z are independently selected from the group consisting of nitrogen, oxygen, sulphur and optionally substituted methylene, provided that when Y is oxygen or sulphur, then R.sub.1 is absent. 2. The compound of claim 1, wherein X is oxygen. 3. The compound of claim 1, wherein Y and Z are each nitrogen. 4. The compound of claim 1, wherein R.sub.c, R.sub.d, R.sub.e and R.sub.f are independently selected from hydrogen and optionally substituted C.sub.1-6 alkyl. 5. The compound of claim 1, wherein A and B together with carbons to which A and B attach represent phenyl, cyclopentyl or cyclohexyl. 6. The compound of claim 1, wherein R is selected from the group consisting of C.sub.1-6 alkyl, phenyl, C.sub.1-6 alkylpyrrolidinyl, C.sub.1-6 haloalkylpyrrolidinyl, C.sub.1-6 cycloalkyl pyrrolidinyl and C.sub.1-6 alkylpiperidyl. 7. The compound of claim 1, which is selected from the group consisting of (2S,3S,4S,5R,6S)-6-(1,3-dimethyl-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]- isoquinoline-5-oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(1-isopropyl-3-methyl-6,7,8,9-tetrahy- dro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)-tetrahydro-2H-pyran-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(1-phenyl-3-methyl-6,7,8,9-tetr- ahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)-tetrahydro-2H-pyran-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-((R)-1-propylpyrrol- idin-2-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahy- dro-2H-pyran-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-((S)-1-propylpyrrolidin-2- -yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H- -pyran-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-propylpyrrolidin-3-yl)- -6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyr- an-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-ethylpyrrolidin-3-yl)-- 6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyra- n-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-(3,3,3-trifluoropropyl- )pyrrolidin-3-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)- tetrahydro-2H-pyran-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-((R)-1-propylpyrrolidin-3- -yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H- -pyran-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-((S)-1-propylpyrrolidin-3- -yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H- -pyran-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(1-(1-ethylpiperidin-2-yl)-3-methyl-6- ,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyran- -2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-propylpiperidin-2-yl)-- 6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyra- n-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3 -methyl-1-(1-propylpiperidin-3-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]i- soquinoline-5-oxy)tetrahydro-2H-pyran-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-propylpiperidin-4-yl)-- 6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyra- n-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-propylpyrrolidin-3-yl)- -3,6,7,8-tetrahydrocyclopentano [d]pyrazolo[3,4-b]pyridine-5-oxy)tetrahydro-2H-pyran-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-propylpyrrolidin-3-yl)- -3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyran-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-cyclopentylpyrrolidin-- 3-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2- H-pyran-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(R)-1-isopropylpyrrolidin- -2-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-- 2H-pyran-2-formic acid; (2S,3S,4S,5R,6S)-3,4,5-triacetyl-6-(1,3-dimethyl-6,7,8,9-tetrahydro-3H-py- razolo[3,4-c]isoquinoline-5-oxy)-tetrahydro-2H-pyran-2-methylformate; (2S,3S,4S,5R,6S)-3,4,5-triacetyl-6-(1-isopropyl-3-methyl-6,7,8,9-tetrahyd- ro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)-tetrahydro-2H-pyran-2-methylforma- te; (2S,3S,4S,5R,6S)-3,4,5-triacetyl-6-(3-methyl-1-phenyl-6,7,8,9-tetrahyd- ro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)-tetrahydro-2H-pyran-2-methylforma- te; (2S,3S,4S,5R,6S)-3,4,5-triacetyl-6-(3-methyl-1-((R)-1-propylpyrrolidin- -2-yl)-6,7,8 ,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyran-2-- methylformate; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-((S)-1-propylpyrrolidin-2- -yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H- -pyran-2-methylformate; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-propylpyrrolidin-3-yl)- -6,7,8,9-tetrahydro-3 H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyran-2-methylformate; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-ethylpyrrolidin-3-yl)-- 6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyra- n-2-methylformate; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-(3,3,3-trifluoropropyl- )pyrrolidin-3-yl)-6,7,8,9-tetrahydro-3 H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyran-2-methylformate; (2S,3S,4S,5R,6S)-3,4,5-triacetyl-6-(3-methyl-1-((R)-1-propylpyrrolidin-3-- yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-- pyran-2-methylformate; (2S,3S,4S,5R,6S)-3,4,5-triacetyl-6-(3-methyl-1-((S)-1-propylpyrrolidin-3 -yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)-tetrahydro-- 2H-pyran-2-methylformate; (2S,3S,4S,5R,6S)-3,4,5-triacetyl-6-(1-(1-ethylpiperidin-2-yl)-3-methyl-6,- 7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyran-- 2-methylformate; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-propylpiperidin-2-yl)-- 6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyra- n-2-methylformate; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-propylpiperidin-3-yl)-- 6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyra- n-2-methylformate; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-propylpiperidin-4-yl)-- 6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyra- n-2-methylformate; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-propylpyrrolidin-3-yl)- -3,6,7,8-tetrahydrocyclopentano[d]pyrazolo[3,4-b]pyridine-5-oxy)tetrahydro- -2H-pyran-2-methylformate; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-propylpyrrolidin-3-yl)- -3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2H-pyran-2-methylformate; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(1-cyclopentylpyrrolidin-- 3-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-2- H-pyran-2-methylformate; and (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(3-methyl-1-(R)-1-isopropylpyrrolidin- -2-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinoline-5-oxy)tetrahydro-- 2H-pyran-2-methylformate. 8. A process for preparing a compound of claim 1, comprising reacting a compound of general formula (XIV) with a compound of general formula (XVI) to obtain a compound of general formula (I), ##STR00015## wherein, W is halogen, and A, B, X, Y, Z, R, R.sub.1,R.sub.c, R.sub.d, R.sub.e and R.sub.f are as defined in claim 1. 9. The method of claim 8, further comprising wherein the compound of general formula (XIV) reacts with the compound of general formula (VI) in the presence of a base. 10. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1. 11. The pharmaceutical composition of claim 10, further comprising an additional active ingredient. 12. The pharmaceutical composition of claim 11, wherein the additional active ingredient is selected from the group consisting of nitrogen mustard, aziridine, methylmelamine, alkyl sulphonate, nitrosourea, triazene, folacin, vinca alkaloid, epipodophyllotoxin, acivicin, aclarubicin, hydrochloride acodazole, acronine, adozelesin, aldesleukin, ambomycin, ametantrone acetate, aminoglutethimide, amsacrine, anastrozole, antramycin, asparaginasum, azithromycin, azacitidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene hydrochloride, bisnafide mesilate, bizelesin, bleomycin sulfate, busulfan, actinomycin C, calusterone, caracemide, carbetimer, carboplatin, carmustine, carubicin hydrochloride, chlorambucil, cirolemycin, cladribine, crisnatol mesilate, cyclophosphamide, cytarabine, dacarbazine, actinomycin D, daunorubicin hydrochloride, decitabine, docetaxel, doxorubicin, doxorubicin, droloxifene hydrochloride, epirubicin hydrochloride, esorubicin hydrochloride, estramustine, etanidazole, etoposide, floxuridine, fluorouracil, flurocitabine gemcitabine, idarubicin hydrochloride, ifosfamide, interleukin II, interferon .alpha.-2a, interferon .alpha.-2b, irinotecan hydrochloride, letrozole, mercaptopurine, methotrexate, metropine, mitomycin, mitoxantrone, paclitaxel, procarbazine, thiotepa, vinblastine, vincristine, camptothecin, hexadecadrol, aspirin, acetaminophen, indometacin, ibuprofen, ketoprofen, meloxicam, corticosteroid and adrenal corticosteroid. 13. A method for treating a disease or condition mediated by poly(ADP-ribose) polymerase (PARP), comprising administering a subject in need thereof a therapeutically effective amount of a compound of claim 1, wherein the disease or condition is breast cancer or malignant melanoma. 14. The method of claim 13, wherein a compound is administered a unit dose of 0.1 mg-1,000 mg. 15. The method of claim 13, further comprising administering to the subject an additional active ingredient. 16. The method of claim 15, wherein the additional active ingredient is selected from the group consisting of nitrogen mustard, aziridine, methylmelamine, alkyl sulphonate, nitrosourea, triazene, folacin, vinca alkaloid, epipodophyllotoxin, acivicin, aclarubicin, hydrochloride, acodazole, acronine, adozelesin, aldesleukin, ambomycin, ametantrone acetate, aminoglutethimide, amsacrine, anastrozole, antramycin, asparaginasum, azithromycin, azacitidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene hydrochloride, bisnafide mesilate, bizelesin, bleomycin sulfate, busulfan, actinomycin C, calusterone, caracemide, carbetimer, carboplatin, carmustine, carubicin hydrochloride, chlorambucil, cirolemycin, cladribine, crisnatol mesilate, cyclophosphamide, cytarabine, dacarbazine, actinomycin D, daunorubicin hydrochloride, decitabine, docetaxel, doxorubicin, doxorubicin, droloxifene hydrochloride, epirubicin hydrochloride, esorubicin hydrochloride, estramustine, etanidazole, etoposide, floxuridine, fluorouracil, flurocitabine, gemcitabine, idarubicin hydrochloride, ifosfamide, interleukin II, interferon .alpha.-2a, interferon .alpha.-2b, irinotecan hydrochloride, letrozole, mercaptopurine, methotrexate, metropine, mitomycin, mitoxantrone, paclitaxel, procarbazine, thiotepa, vinblastine, vincristine, camptothecin, hexadecadrol, aspirin, acetaminophen, indometacin, ibuprofen, ketoprofen, meloxicam, corticosteroid and adrenal corticosteroid. 17. The method of claim 16, wherein the therapeutically effective amount of a compound and the additional active ingredient are simultaneously, synergistically, separately or sequentially administered to the subject.

Details for Patent 9,249,172

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992		2030-05-24